Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
AdipoGen Life Sciences
DMAT
40
CHF
CHF 40.00
In stock
AG-CR1-3654-M0011 mgCHF 40.00
AG-CR1-3654-M0055 mgCHF 160.00
AG-CR1-3654-M02525 mgCHF 480.00
| Product Details | |
|---|---|
| Synonyms | 2-Dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole; 4,5,6,7-Tetrabromo-N,N-dimethyl-1H-benzimidazol-2-amine |
| Product Type | Chemical |
| Properties | |
| Formula |
C9H7Br4N3 |
| MW | 476.8 |
| CAS | 749234-11-5 |
| Purity Chemicals | ≥96% (HPLC) |
| Appearance | Solid. |
| Solubility | Soluble in DMSO (10mg/ml). |
| Identity | Determined by 1H-NMR. |
| InChi Key | SLPJGDQJLTYWCI-UHFFFAOYSA-N |
| Smiles | CN(C)C1=NC2=C(Br)C(Br)=C(Br)C(Br)=C2N1 |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Handling Advice | Keep cool and dry. |
| Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
Description
- Potent high affinity ATP-competitive inhibitor of casein kinase II (CK2) (IC50=0.13µM). Inhibits CK2 in rat liver with >1000-fold greater selectivity for CK2 than for CK1 (IC50=140nM and >200 μM, respectively).
- DYRK1A and DYRK2 inhibitor (IC50= ~0.4µM for both).
- Shown to inhibit additional kinases, such as PIM1, PIM3, HIPK2, HIPK3, PKD1 and CDK2 in the submicromolar range.
- Anticancer agent. Apoptosis inducer in different cancer cell lines.
- Induces reactive oxygen species (ROS) and DNA double strand breaks in tumor cells.
- Induces apoptosis in cells expressing an inhibitor-resistant CK2, by inhibiting quinone reductase 2 (NQO2), binding with similar affinities to the oxidized and reduced forms of NQO2.
- Useful for in vivo studies due to cell permeability and high efficacy in cultured cells and implications in research and treatment of neoplasia and infective diseases, in which CK2 plays a role.
Product References
- Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole: M.A. Pagano, et al.; J. Med. Chem. 47, 6239 (2004)
- 2-Dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole: a novel powerful and selective inhibitor of protein kinase CK2: M.A. Pagano, et al.; BBRC 321, 1040 (2004)
- Induction of cell death in antiestrogen resistant human breast cancer cells by the protein kinase CK2 inhibitor DMAT: C.W. Yde, et al.; Cancer Lett. 256, 229 (2007)
- The selectivity of inhibitors of protein kinase CK2: an update: M.A. Pagano, et al.; Biochem. J. 415, 353 (2008)
- DMAT, an inhibitor of protein kinase CK2 induces reactive oxygen species and DNA double strand breaks: C.C. Schneider, et al.; Oncol. Rep. 21, 1593 (2009)
- Anti-neoplastic effect of protein kinase CK2 inhibitor, 2-dimethylamino-4,5,6,7-tetrabromobenzimidazole (DMAT), on growth and hormonal activity of human adrenocortical carcinoma cell line (H295R) in vitro: H. Lawnicka, et al.; Cell Tissue Res. 340, 371 (2010)
- Inhibition of experimental HCC growth in mice by use of the kinase inhibitor DMAT: G. Sass, et al.; Int. J. Oncol. 39, 433 (2011)
- Quinone reductase 2 is an adventitious target of protein kinase CK2 inhibitors TBBz (TBI) and DMAT: K.K. Leung & B.H. Shilton; Biochemistry 54, 47 (2015)
Related Products
